A potential Covid-19 drug from Gilead Sciences Inc. did well in two important clinical trials that revealed early data Wednesday.
The experimental antiviral drug, called remdesivir, showed promise when doctors in China and Italy unleashed it against the effects of the novel coronavirus that causes Covid-19. The study results ? preliminary data from a Gilead-sponsored trial and another led by the National Institute of Allergy and Infectious Diseases ? appear to back up the anecdotal findings?